X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-09-17 | AVIR | Atea Pharmaceuticals, Inc. | Sommadossi Jean-Pierre | Pres, CEO,, COB | S - Sale | $4.04 | -57,969 | 5,982,582 | -1% | -$234,155 | |||||
| M | 2024-09-17 | BGNE | Beigene, Ltd. | Wu Xiaobin | Pres, COO, GM China | S - Sale | $200.12 | -5,000 | 1,087,692 | 0% | -$1,000,615 | |||||
| M | 2024-07-03 | CDT | Conduit Pharmaceuticals Inc. | Regan Andrew | Dir, 10% | S - Sale | $0.30 | -15,301,068 | 244,277 | -98% | -$4,592,487 | |||||
2024-09-18 | DYN | Dyne Therapeutics, Inc. | High Susanna Gatti | COO | S - Sale | $34.41 | -8,976 | 131,636 | -6% | -$308,864 | ||||||
2024-09-18 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $34.55 | -1,390 | 98,568 | -1% | -$48,025 | ||||||
2024-09-18 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $34.55 | -2,339 | 140,375 | -2% | -$80,812 | ||||||
| D | 2024-09-18 | SPRY | Ars Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Officer | S - Sale+OE | $14.00 | -10,000 | 5,693 | -64% | -$140,000 | |||||
| D | 2024-09-17 | RYTM | Rhythm Pharmaceuticals, Inc. | Good Jennifer L | Dir | S - Sale+OE | $52.40 | -31,751 | 3,000 | -91% | -$1,663,803 | |||||
2024-09-17 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $12.93 | -100,000 | 11,965,600 | -1% | -$1,293,205 | ||||||
2024-09-17 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $12.93 | -100,000 | 11,965,600 | -1% | -$1,293,205 | ||||||
| M | 2024-09-17 | RPHM | Reneo Pharmaceuticals, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.36 | +56,106 | 4,379,818 | +1% | +$76,237 | |||||
| DM | 2024-09-16 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale+OE | $27.54 | -8,393 | 75,294 | -10% | -$231,175 | |||||
| D | 2024-09-16 | BCAX | Bicara Therapeutics Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $18.00 | +1,833,000 | 2,652,575 | +224% | +$32,994,000 | |||||
2024-09-16 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale | $98.92 | -32,795 | 33,300 | -50% | -$3,244,140 | ||||||
| D | 2024-09-16 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $96.47 | -8,000 | 33,300 | -19% | -$771,798 | |||||
2024-09-16 | VSTM | Verastem, Inc. | Gagnon Robert E. | Dir | S - Sale | $2.80 | -287 | 35,023 | -1% | -$804 | ||||||
2024-09-16 | VSTM | Verastem, Inc. | Stuglik Brian M | Dir | S - Sale | $2.80 | -600 | 96,445 | -1% | -$1,680 | ||||||
2024-09-16 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $2.80 | -246 | 232,572 | 0% | -$689 | ||||||
2024-09-16 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $22.41 | -1,270 | 194,428 | -1% | -$28,458 | ||||||
| D | 2024-09-16 | ZBIO | Zenas Biopharma, Inc. | Enavate Sciences Gp, LLC | 10% | P - Purchase | $17.00 | +882,353 | 3,761,359 | +31% | +$15,000,001 | |||||
| M | 2024-09-16 | PMN | Promis Neurosciences Inc. | Gordon Michael S | 10% | P - Purchase | $1.25 | +93,223 | 2,217,185 | +4% | +$116,880 | |||||
2024-09-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Pres, CEO | S - Sale | $1.80 | -14,550 | 752,266 | -2% | -$26,132 | ||||||
2024-09-17 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Chief Commercial Officer | S - Sale | $1.78 | -2,608 | 162,659 | -2% | -$4,650 | ||||||
2024-09-17 | OPTN | Optinose, Inc. | Marino Michael F III | GC, Corp Sec | S - Sale | $0.87 | -3,226 | 547,238 | -1% | -$2,807 | ||||||
2024-09-17 | OPTN | Optinose, Inc. | Mahmoud Ramy A | CEO | S - Sale | $0.87 | -4,881 | 1,374,519 | 0% | -$4,246 | ||||||
2024-09-16 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $47.41 | -1,500 | 40,405 | -4% | -$71,115 | ||||||
| M | 2024-09-16 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $35.10 | -4,592 | 6,189,195 | 0% | -$161,198 | |||||
| DM | 2024-09-16 | FHTX | Foghorn Therapeutics Inc. | Costa Carlos | Chief People Officer | S - Sale+OE | $10.04 | -10,672 | 0 | -100% | -$107,131 | |||||
2024-09-16 | EMMA | Emmaus Life Sciences, Inc. | Lim Seah H. | Dir | P - Purchase | $0.04 | +20,000 | 4,606,626 | 0% | +$800 | ||||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Weber Steven | Principal Accounting Officer | S - Sale | $11.54 | -469 | 25,543 | -2% | -$5,412 | ||||||
| AD | 2024-09-16 | ZBIO | Zenas Biopharma, Inc. | Fairmount Funds Management LLC | Dir | P - Purchase | $17.00 | +300,000 | 1,892,806 | +19% | +$5,100,000 | |||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Takimoto Chris H | Chief Medical Officer | S - Sale | $11.54 | -1,487 | 154,331 | -1% | -$17,158 | ||||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $11.54 | -1,487 | 122,694 | -1% | -$17,158 | ||||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Schwarzer Fred | CEO, Pres | S - Sale | $11.54 | -3,946 | 446,842 | -1% | -$45,532 | ||||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Keyt Bruce | Chief Scientific Officer | S - Sale | $11.54 | -1,487 | 246,987 | -1% | -$17,158 | ||||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Harler Mary Beth | Head, Research, Autoimmunity | S - Sale | $11.54 | -1,487 | 163,740 | -1% | -$17,158 | ||||||
2024-09-13 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $11.54 | -925 | 79,104 | -1% | -$10,673 | ||||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Mathers Edward T | Dir, 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Baskett Forest | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Behbahani Ali | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Chang Carmen | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Florence Anthony A. Jr. | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Makhzoumi Mohamad | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Walker Paul Edward | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Yang Rick | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Sandell Scott D | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Orbimed Advisors LLC | Dir, 10% | P - Purchase | $16.00 | +750,000 | 3,812,215 | +24% | +$12,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | New Enterprise Associates 17, L.P. | 10% | P - Purchase | $16.00 | +500,000 | 3,614,486 | +16% | +$8,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Frazier Life Sciences X, L.P. | 10% | P - Purchase | $16.00 | +625,000 | 4,552,774 | +16% | +$10,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Heron Patrick J | Dir, 10% | P - Purchase | $16.00 | +625,000 | 4,552,774 | +16% | +$10,000,000 | |||||
| M | 2024-09-13 | YMAB | Y-Mabs Therapeutics, Inc. | Gad Thomas | CHIEF BUSINESS OFFICER | S - Sale | $13.31 | -95,000 | 286,381 | -25% | -$1,264,650 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Aynechi Tiba | Dir | P - Purchase | $16.00 | +750,000 | 2,136,335 | +54% | +$12,000,000 | |||||
| D | 2024-09-16 | MBX | Mbx Biosciences, Inc. | Gordon Carl L | Dir, 10% | P - Purchase | $16.00 | +750,000 | 3,812,215 | +24% | +$12,000,000 | |||||
2024-09-13 | ZBIO | Zenas Biopharma, Inc. | Lu Hongbo | Dir | P - Purchase | $17.00 | +58,823 | 58,823 | New | +$999,991 | ||||||
2024-09-12 | TERN | Terns Pharmaceuticals, Inc. | Lu Hongbo | Dir | P - Purchase | $10.50 | +476,190 | 476,190 | New | +$4,999,995 | ||||||
| D | 2024-09-16 | BTAI | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | S - Sale+OE | $0.69 | -355 | 14,203 | -2% | -$245 | |||||
| D | 2024-09-16 | BTAI | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO, Pres, 10% | S - Sale+OE | $0.69 | -1,982 | 7,739,167 | 0% | -$1,367 | |||||
| D | 2024-09-16 | BTAI | Bioxcel Therapeutics, Inc. | Steinhart Richard I | CFO | S - Sale+OE | $0.69 | -356 | 6,204 | -5% | -$246 | |||||
| D | 2024-09-16 | BTAI | Bioxcel Therapeutics, Inc. | Rodriguez Javier | See Remarks | S - Sale+OE | $0.69 | -345 | 9,133 | -4% | -$238 | |||||
| D | 2024-09-16 | BTAI | Bioxcel Therapeutics, Inc. | O'Neill Vincent | See Remarks | S - Sale+OE | $0.69 | -138 | 3,907 | -3% | -$95 | |||||
| D | 2024-09-16 | BTAI | Bioxcel Therapeutics, Inc. | Wiley Matthew T. | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $0.69 | -215 | 4,033 | -5% | -$149 | |||||
| DM | 2024-09-16 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $39.40 | -12,500 | 3,240 | -79% | -$492,461 | |||||
| D | 2024-09-16 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $38.93 | -2,220 | 15,398 | -13% | -$86,425 | |||||
| D | 2024-09-16 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $39.91 | -12,220 | 4,744 | -72% | -$487,725 | |||||
2024-09-17 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $10.31 | +351 | 108,342 | 0% | +$3,618 | ||||||
| D | 2024-09-17 | BCAX | Bicara Therapeutics Inc. | Flynn James E | Possible Members of 10% Group, 10% | P - Purchase | $18.00 | +70,000 | 1,795,174 | +4% | +$1,260,000 | |||||
2024-09-16 | EQ | Equillium, Inc. | Tom Penny | Principal Accounting Officer | S - Sale | $0.85 | -38,806 | 10,051 | -79% | -$32,985 | ||||||
2024-09-16 | APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Dir | S - Sale | $36.23 | -37,000 | 247,526 | -13% | -$1,340,597 | ||||||
2024-09-13 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $10.53 | -67,400 | 16,859,075 | 0% | -$709,756 | ||||||
2024-09-13 | COLL | Collegium Pharmaceutical, Inc | Smith Thomas B | EVP, Chief Medical Officer | S - Sale | $36.62 | -9,593 | 53,816 | -15% | -$351,320 | ||||||
| D | 2024-09-16 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $339.12 | -7,810 | 4,264 | -65% | -$2,648,527 | |||||
| D | 2024-09-17 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $56.77 | -7,300 | 120,920 | -6% | -$414,401 | |||||
| D | 2024-09-13 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | S - Sale+OE | $48.26 | -3,000 | 223,056 | -1% | -$144,785 | |||||
| D | 2024-09-13 | SUPN | Supernus Pharmaceuticals, Inc. | Gemayel Georges | Dir | S - Sale+OE | $31.33 | -13,886 | 13,315 | -51% | -$435,048 | |||||
| D | 2024-09-16 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $55.99 | -5,000 | 401,622 | -1% | -$279,950 | |||||
2024-09-16 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $36.21 | -192 | 38,141 | -1% | -$6,952 | ||||||
2024-09-13 | FLGC | Flora Growth Corp. | Starke Clifford | CEO | P - Purchase | $0.95 | +6,795 | 1,346,902 | +1% | +$6,455 | ||||||
2024-09-12 | XCUR | Exicure, Inc. | Dgp Co., Ltd. | 10% | P - Purchase | $3.00 | +237,223 | 849,223 | +39% | +$711,669 | ||||||
| D | 2024-09-16 | ZBIO | Zenas Biopharma, Inc. | Enright Patrick G | Dir | P - Purchase | $17.00 | +440,000 | 774,530 | +132% | +$7,480,000 | |||||
| D | 2024-09-16 | ZBIO | Zenas Biopharma, Inc. | Nunn Jason Raleigh | Dir | P - Purchase | $17.00 | +882,352 | 3,056,801 | +41% | +$14,999,984 | |||||
| D | 2024-09-16 | ZBIO | Zenas Biopharma, Inc. | Fairmount Funds Management LLC | Dir | P - Purchase | $17.00 | +300,000 | 1,604,891 | +23% | +$5,100,000 | |||||
| D | 2024-09-16 | ZBIO | Zenas Biopharma, Inc. | Sr One Capital Management, LLC | 10% | P - Purchase | $17.00 | +2,235,294 | 4,911,539 | +84% | +$37,999,998 | |||||
| M | 2024-09-12 | MREO | Mereo Biopharma Group Plc | Scots-Knight Denise | CEO | S - Sale | $4.30 | -88,657 | 808,921 | -10% | -$381,423 | |||||
| M | 2024-09-12 | MREO | Mereo Biopharma Group Plc | Lewicki John A. | Chief Scientific Officer | S - Sale | $4.30 | -16,149 | 92,826 | -15% | -$69,477 | |||||
| M | 2024-09-12 | MREO | Mereo Biopharma Group Plc | Sermon Charles | GC | S - Sale | $4.30 | -30,926 | 219,061 | -12% | -$133,051 | |||||
| M | 2024-09-12 | MREO | Mereo Biopharma Group Plc | Fox Christine Ann | CFO | S - Sale | $4.30 | -28,286 | 89,285 | -24% | -$121,693 | |||||
| M | 2024-09-12 | MREO | Mereo Biopharma Group Plc | Hughes-Wilson Alexandra | See Remarks | S - Sale | $4.30 | -148,110 | 50,475 | -75% | -$637,203 | |||||
| D | 2024-09-16 | LBPH | Longboard Pharmaceuticals, Inc. | Kaye Randall | CMO | S - Sale+OE | $31.64 | -16,666 | 17,920 | -48% | -$527,318 | |||||
2024-09-12 | SER | Serina Therapeutics, Inc. | Mintz Steven | Dir | P - Purchase | $6.47 | +6,000 | 38,230 | +19% | +$38,814 | ||||||
2024-09-13 | ARDX | Ardelyx, Inc. | Rosenbaum David P. | Chief Development Officer | S - Sale | $6.26 | -5,312 | 582,718 | -1% | -$33,254 | ||||||
2024-09-12 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | P - Purchase | $2.53 | +40,000 | 259,995 | +18% | +$101,368 | ||||||
2024-09-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $56.82 | -250 | 56,738 | 0% | -$14,205 | ||||||
| D | 2024-09-13 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $74.35 | -27,871 | 67,856 | -29% | -$2,072,223 | |||||
| DM | 2024-09-12 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $74.91 | -41,040 | 106,134 | -28% | -$3,074,177 | |||||
2024-09-12 | ANNX | Annexon, Inc. | Yednock Ted | EVP, CHIEF INNOVATION OFFICER | S - Sale | $6.16 | -5,500 | 75,865 | -7% | -$33,880 | ||||||
| M | 2024-09-12 | RPHM | Reneo Pharmaceuticals, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.35 | +358,923 | 4,323,712 | +9% | +$484,344 | |||||
2024-09-12 | LQDA | Liquidia Corp | Manning Paul B | Dir | P - Purchase | $8.90 | +337,078 | 6,602,551 | +5% | +$2,999,994 | ||||||
2024-09-16 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.16 | +100,000 | 1,100,000 | +10% | +$15,600 | ||||||
2024-09-12 | SCYX | Scynexis Inc | Angulo Gonzalez David | CEO | P - Purchase | $1.37 | +20,000 | 507,871 | +4% | +$27,400 | ||||||
2024-08-12 | GLSI | Greenwich Lifesciences, Inc. | Thompson Jaye | VP Clinical Reg Affairs | P - Purchase | $13.85 | +800 | 263,148 | 0% | +$11,080 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |